Jamey P Weichert
Overview
Explore the profile of Jamey P Weichert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kerr C, Jin W, Liu P, Grudzinski J, Ferreira C, Rojas H, et al.
bioRxiv
. 2025 Jan;
PMID: 39763914
Radiopharmaceutical therapy (RPT) enhances tumor response to immune checkpoint inhibitors (ICI) in preclinical models, but the effects of different radioisotopes have not been thoroughly compared. To evaluate mechanisms of response...
2.
Kerr C, Sheehan-Klenk J, Grudzinski J, Adam D, Nguyen T, Ferreira C, et al.
bioRxiv
. 2024 Jul;
PMID: 39071353
Teaser: This study describes the time course and nature of tumor immunomodulation by radiopharmaceuticals with differing physical properties.
3.
Muralidhar A, Hernandez R, Morris Z, Rojas H, Idrissou M, Weichert J, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38663936
Rationale: Androgen deprivation therapy (ADT) is pivotal in treating recurrent prostate cancer and is often combined with external beam radiation therapy (EBRT) for localized disease. However, for metastatic castration-resistant prostate...
4.
Marsh I, Li C, Grudzinski J, Jeffery J, Longhurst C, Adam D, et al.
Cancer Biother Radiopharm
. 2023 Apr;
38(7):458-467.
PMID: 37022739
Delivery of radiotherapeutic dose to recurrent head and neck cancer (HNC) is primarily limited by locoregional toxicity in conventional radiotherapy. As such, HNC patients stand to benefit from the conformal...
5.
Pinchuk A, Rampy M, Longino M, Durkee B, Counsell R, Weichert J
Pharmaceutics
. 2023 Jan;
15(1).
PMID: 36678801
We have previously described the remarkable capacity of radioiodinated alkyl phospholipids to be sequestered and retained by a variety of tumors in vivo. We have already established the influence of...
6.
Kerr C, Grudzinski J, Nguyen T, Hernandez R, Weichert J, Morris Z
Pharmaceutics
. 2023 Jan;
15(1).
PMID: 36678756
Targeted radionuclide therapy (TRT) and immunotherapy are rapidly growing classes of cancer treatments. Basic, translational, and clinical research are now investigating therapeutic combinations of these agents. In comparison to external...
7.
Carlson P, Patel R, Birstler J, Rodriquez M, Sun C, Erbe A, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36639155
Background: The antitumor effects of external beam radiation therapy (EBRT) are mediated, in part, by an immune response. We have reported that a single fraction of 12 Gy EBRT combined...
8.
Zhang R, Choi C, Brunnquell C, Hernandez R, Pinchuk A, Grudzinski J, et al.
Invest Radiol
. 2022 Sep;
57(10):655-663.
PMID: 36069439
Objectives: In an effort to exploit the elevated need for phospholipids displayed by cancer cells relative to normal cells, we have developed tumor-targeted alkylphosphocholines (APCs) as broad-spectrum cancer imaging and...
9.
Potluri H, Ferreira C, Grudzinski J, Massey C, Aluicio-Sarduy E, Engle J, et al.
J Immunother Cancer
. 2022 Aug;
10(8).
PMID: 36002185
Background: Systemic radiation treatments that preferentially irradiate cancer cells over normal tissue, known as targeted radionuclide therapy (TRT), have shown significant potential for treating metastatic prostate cancer. Preclinical studies have...
10.
Magee K, Marsh I, Turek M, Grudzinski J, Aluicio-Sarduy E, Engle J, et al.
PLoS One
. 2021 Aug;
16(8):e0255798.
PMID: 34383787
Rationale: Murine syngeneic tumor models have revealed efficacious systemic antitumor responses following primary tumor in situ vaccination combined with targeted radionuclide therapy to secondary or metastatic tumors. Here we present...